Insys Therapeutics Announces Senior Management Changes and Appointments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Subsys Pushes Insys Therapeutics (INSY) to 3Q Beat; Piper Jaffray Reiterates Overweight
November 6, 2015 9:57 AM ESTPiper Jaffray reiterated an Overweight rating on INSYS Therapeutics (NASDAQ: INSY), and raised the price target to $49.00 (from $48.00), following the company's 3Q15 earnings report. Insys reported 3Q15 EPS of $0.50, on revenues of $91M, well ahead of Street estimates. Subsys once again showed strong sequential growth, with sequential sales growth of 19% over 2Q15. Management suggested... More
Insys Therapeutics (INSY) CEO Babich Steps Down
November 5, 2015 6:59 AM ESTInsys Therapeutics, Inc. (NASDAQ: INSY) announced that Michael L. Babich has stepped down as President and Chief Executive Officer of Insys. The Board of Directors has appointed Dr. John N. Kapoor as President and Chief Executive Officer effective November 4, 2015. Dr. Kapoor will continue to serve of the Chairman of the Companys Board of Directors. Daniel Brennan has been appointed Executive Vice President and Chief Operating Officer effective November 1, 2015.
It has been a privilege to lead Insys for the past six... More
